s President Trump tweets yet another promise to lower drug prices, a new analysis offers an example of what can happen when the federal government negotiates with manufacturers.

During a 12-month period ended November 2015, the Veterans Choice Program, which was created by the US Department of Veterans Affairs, paid a median price of $12,500 for a month’s supply of Harvoni, a hepatitis C drug sold by Gilead Sciences. Since most patients typically are treated for two to three months, the cost was closer to $25,000 to $37,500 per person, according to the analysis in Medical Care.

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Comment

Please enter your name.
Please enter a comment.

  • I’m a Vietnam Vet and about to start this treatment I feel bad that these drugs are so inflated and we all pay the price. I may die without the drug so I thank all the taxpayers and condem the drug companies for their greed. Make a profit, but stop ripping off both sick and healthy people at the same time. As a conservative, I hate to say it, but maybe regulation is the answer.

  • Essentially therefore, the VA is “doing more [about prices] with less [ok, fewer]” – food for thought. That said, the law still has to change for Medicare to negotiate.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.